HeartBeam (NASDAQ: BEAT) has revealed positive results today from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment presented by Graham Nichol, MD, MPH, FRCP(C), of the University of Washington, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego.
According to HeartBeam, its portable, cable-free, credit-card-sized device enables patients to record their own ECG on-demand, wherever they are. Unlike conventional wearables, HeartBeam captures three-dimensional electrical information from the heart, giving physicians a more complete picture for comprehensive evaluation.
In a statement, Dr. Nichol commented, “Obtaining a clinically meaningful recording of the heart’s electrical activity at the time of symptom onset could help physicians assess whether a patient may be experiencing a heart attack and reduce time to intervention. In the ALIGN-ACS pilot study, patients were able to record their own ECGs with the HeartBeam device under clinical supervision. A cardiologist’s review of that patient-recorded ECG could help patients at home decide whether to seek care. These early findings demonstrate the potential of this technology to help shorten time to care for patients experiencing a heart attack.”
